+351 211 369 829 
New ambition, new image!
Ophiomics was founded in 2015 as clinical testing laboratory. In 2020, with the support of the EIC Accelerator grant and from the EIC Fund, we pivoted
Ophiomics @ Arab Health 2023
🚀Off to #ArabHealth2023 with the #EUeic Overseas Trade Fairs ✈️Programme 2.0! Pay us a visit at the European Pavilion (Za’abeel&nbs
Ophiomics secures Series A investment
Ophiomics secured a Series A investment round to support commercial development and continued technical/clinical development of its flagship product H
in the news
https://ec.europa.eu/research-and-innovation/en/horizon-magazine/silent-killer-liver-cancer-prompts-race-improve-organ-replacements
Ophiomics @ 4th meeting of Translational Hepatology
Discussing translational research in Liver Cancer, in particular the role of SMEs in IVD development.
Ophiomics @ Precision Medicine Forum (PT)
Presenting HepatoPredict and discussing the development of new precision medicine solutions
Ophiomics @ PT GI cancer meeting
We presented HepatoPredict to an assembly of GastroEnterologists, Oncologists, Surgeons and other medical professionals in the Portuguese GI cancer me
Ophiomics @ European Congress of Pathology
Ophiomics attending the European Congress of Pathology (ECP) Ophiomics is attending ECP from 3-7 of September in Basel, Switzerland. We are be pr
HepatoPredict first clinical validation published in Annals of Surgery
Our paper “A gene expression signature to select hepatocellular carcinoma patients for liver transplantation” is finally out and can be found 
DNA methylation fingerprint of hepatocellular carcinoma …
As part of our Liquid Biopsy development pipeline, we are identifying biomarkers and developing algorithms that can change the way liver cancer is det
